The HAT activity of p300/CBP is often aberrantly controlled in human disease, and targeting p300/CBP has been shown to produce antitumor effects in vitro against several hematological malignancies, prostate and colorectal cancers (Du et al., 2017; Lasko et al., 2017). The gene discussed is EP300; the disease is hematologic disorder.